Abstract: Regulatory T cells (Tregs) are important members of the immune system regulating the host responses to infection and neoplasms. Tregs prevent autoimmune disorders by protecting the host-cells from an immune response, related to the peripheral tolerance. However, tumor cells use Tregs as a shield to protect themselves against anti-tumor immune response. Thus, Tregs are a hurdle in achieving the complete potential of anti-cancer therapies including immunotherapy. This has prompted the development of novel adjuvant therapies that obviate their negative effects thereby enhancing the therapeutic efficacy. Our earlier studies have shown the efficacy of the glycolytic inhibitor, 2-deoxy-D-glucose (2-DG) by reducing the induced Tregs pool and enhance immune stimulation as well as local tumor control. These findings have suggested its potential for enhancing the efficacy of immunotherapy, besides radiotherapy and chemotherapy. This review provides a brief account of the current status of Tregs as a component of the immune-biology of tumors and various preclinical and clinical strategies pursued to obviate the limitations imposed by them in achieving therapeutic efficacy.
Introduction
Cancer accounts for the major cause of death after cardiovascular disorders worldwide. 1 Cancer primarily is a disease that arises due to the deregulation of the growth of functionally matured (somatic) cells leading to a state of "malignant" behavior, which is reflected in the well-established hallmarks of the disease as described by Hanahan and Weinberg. 2 Several pioneering studies over the past few years have established immune evasion as one of the key events for the successful establishment of tumors. 3 Cancer cells modulate several pathways leading defective antigen presentation, secretion of immunosuppressive mediators, tolerance and immune deviation, apoptosis and release of immunosuppressive cells to evade immune responses 4 ( Figure 1 ). Recruitment of immunosuppressive cells like myeloid-derived suppressor cells (MDSCs), tumor-derived macrophages, modulated dendritic cells (DCs) and T-regulatory cells (Tregs), are important mechanisms underlying the immune evasion achieved by cancer cells. Among these immunosuppressive cells, the master regulatory cells, Tregs not only secrete molecules that promote initiation and progression of tumors, but also induce neoangiogenesis facilitating metastasis. [5] [6] [7] The role of Tregs has also been well established in pathogenic infections and allergic response. 8, 9 Despite more than 20 years of their identification, unraveling of their role in many disease states, the precise mechanisms underlying their suppressive function remains to be completely understood. 10 In a disease state such as cancer, Tregs become an impediment as they compromise the anti-tumor response of the host by dampening the efficiency of T-effector (Teff) cells. Therefore, maintaining an optimum balance between Treg and Teff cells is vital in not only avoiding autoimmunity, but also keeping in check the progression of malignancy, avoiding therapeutic resistance, leading to better prognosis of patients ( Figure 2 ). Emerging evidences suggest that the avoidance of tumor cell death from therapeutic agents is linked to the up-regulation of the Treg pool and escape from immune response. [11] [12] [13] [14] [15] [16] [17] [18] Therefore, therapeutic approaches, which also modify Tregs appear to be successful in the management of tumors. Several mechanisms appear to be involved in Treg-mediated immunosuppression including the down- 20 We present here an overview on the existing knowledge about the role of Tregs in tumorigenesis as well as merits and limitations of approaches using conventional chemotherapeutic agents that target Tregs for improving therapeutic gain. Some new agents that also target Tregs and show negligible or absence of any side effects on normal cells are also discussed (Table 1) . FoxP3 plays an important role in the generation and production of Tregs, including the maintenance of their functionality; loss of which is associated with immune dysregulation and lymphoproliferative diseases both in mice and humans. 21 Tregs have two subtypes on the basis of their origin: naturally occurring Tregs (n-Tregs) and inducible Tregs (i-Tregs). n-Tregs are mainly formed in thymus and need costimulatory molecules for their development and lineage commitment. 12 i-Tregs are generated in the periphery and do not require costimulatory molecules for activation, but at least require T cell receptor (TCR), TGF-β and IL-2 under a variety of pathological conditions. 8 i-Tregs mediate immunosuppression in multiple ways that involve the secretion of immunosuppressive cytokines (interleukins, IL-10, IL-35, and TGF-β), granzymes-induced cytolysis, metabolic reprogramming of effector cells, and DC-mediated suppression. 22, 23 In vivo studies in mice models indicate that Tregs regulate concomitant immunity and cross-reactive antitumor immunity. 24, 25 55 In mice and humans, the high glycolytic rate is due to hyper-activation of the mTOR signaling pathway and is operative during nutrient-deprived conditions. 54, 56 Contrarily, Tregs have higher metabolic flexibility compared to CD4 + Teff cells. During Treg proliferation enhanced glycolysis not only provides energy in the form of ATP and NADH but also relays its metabolic intermediates to nucleotide biosynthetic pathways. 54 Also, during low energy conditions, Tregs rely on fatty acid oxidation (FAO), due to the increased level of carnitine palmitoyltransferase 1a (CPT1a), which is critical for FAO as a rate-limiting enzyme. This facilitates the acyl groups to enter into the mitochondria thereby suggesting that Tregs use multiple metabolic pathways needed for extensive proliferation.
Tregs Characterization And Immune Evasion
Apart from development and proliferation, the intra-tumoral migration of Tregs also contributes to its immunosuppressive activity. Tumors secret several chemokines like C-C motif chemokine ligand 22 (CCL22), which is a ligand to C-C chemokine receptor (CCR) 4 present on Tregs, thereby attracting them near to the tumor tissue as observed in human ovarian cancers. The alpha chain of heterotrimeric IL-2 receptor complex, CD25 has an inevitable role in both the Treg development and their activity and can, therefore, be exploited as a potential target against Tregs. 22 IL-2 is generally essential for proliferation of the activated T cells. Due to the upregulated expression of CD25 on Tregs, most of the IL-2 present in the milieu is utilized by the Tregs present in the vicinity, thereby preventing Teff cells from proliferation and sustained survival. 61 The depletion of CD25 positive
Treg population via targeted antibody therapy enhanced the anti-tumor immunity that correlated well with the progressive reduction of tumor volume in murine cancer models. 62, 63 A phase-I/II study with daclizumab (that blocks CD25) in combination with the DC vaccine has shown a transient but complete depletion of CD25 high cells in melanoma patients. 64 Similarly, in metastatic melanoma patients (with lymphopenia induced via temozolomide), anti-CD25 antibody depleted Tregs significantly without impairing Teff cell functions, thereby augmenting the antitumor immune response. 65 Administration of daclizumab has also been found to decrease Tregs in the peripheral blood mononuclear cells (PBMCs) of patients with melanoma. 66 Since, CD25 is also present on the Teff cells, targeting Tregs with CD25 blockade is also expected to collaterally deplete Teff cells due to IL-2 deprivation, which may lead to opportunistic infections in patients receiving the treatment. 67 Furthermore, daclizumab has a short half-life of 20 days and therefore has a transient effect, which is reversible under in-vitro conditions. 61 Other limitations of CD25 blockade include side effects such as severe acute hypersensitivity reactions, cytokine release syndrome, infections, and local skin reactions. 68 Daclizumab marketed for relapsed multiple sclerosis has been withdrawn from the market due to deadly episodes of encephalitis and meningoencephalitis. 69 Interestingly, it has been reported that treating metastatic melanoma patients with anti-CD25 RFT5-SMPT-dgA (IMTOX25) leads to a significant but transient decrease in Treg numbers. However, the desired anti-tumor activity was not observed. 70 Despite the preliminary success, many questions still need to be addressed before developing a successful therapeutic strategy exploiting CD25 as a potential target for Tregs depletion.
Antibody Against CTLA-4 showed an excellent 18-28% objective therapeutic response in patients with advanced non-small-cell lung carcinoma, melanoma, and renal cell carcinoma. 86 Interestingly, patients that were cured and showed no signs and symptoms of the disease exhibited high Treg levels after nivolumab therapy while relapsing patients did not. 21, 87 The differential response was attributed to high pSTAT3 (phospho-signal transducer and activator of transcription) level and IL-10 production following nivolumab. 87 Thus, the relationship between anti-PD-1 blockade based immunotherapy and Treg levels need extensive investigation in cancer patients including their response to combinational therapies involving inhibitors of immune checkpoint (agents that inhibit the activity of proteins involved in the suppression of anti-tumor immunity like PD-1 and CTLA-4).
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Antibody Against GITR GITR, (glucocorticoid-induced TNFR family related gene) is a member of the TNFR superfamily (TNFRSF) and a co-stimulatory molecule that is expressed in resting CD4 + and CD8 + population and increases in expression upon T-cell activation. 89 It has also been shown that GITR is expressed constitutively at a high level in Tregs 36,90 and treatment with anti-GITR agonistic mAb reduces the suppressive activity of Tregs. 91 A study in GITR knockout mice, which lack GITR signaling, reported that the responder CD4 + CD25 − population becomes resistant to the suppressive CD4 + CD25 + population. 91 Furthermore, the use of anti-GITR mAb has been shown to elevate CD4 + and CD8 + T cell response against tumor cells, an effect especially seen in large tumors. 88 OX40 deficient conditions. Moreover, intra-tumoral anti-OX40 injection induces the migration of infiltrating DCs to draining lymph nodes and deploys a population of newlyformed cytotoxic T-lymphocytes (CTLs) that are tumorspecific. 99 Recently, an intra-tumoral injection of agonist OX86 mAb that stimulates OX40 significantly reduced the immunosuppression mediated by the Tregs thereby increasing an activation of Teff cells in a murine cancer model. 100 Moreover, the tumor-infiltrating Tregs produced less IL-10 in response to the treatment, besides resulting in DC maturation (in-vitro) and DC migration (in-vivo), leading to augmented tumor immunity. Administration of anti-OX40 fusion protein OX40-Fc has been found to result in the regression of murine sarcoma, supporting this proposition. 101 The combined use of cyclophosphamide and anti-OX40 mAb has shown a significant increase in immune responses against tumors by depleting Tregs in tumor vicinity and simultaneously inducing an influx of CD8 + Teff cells in B16 melanoma murine models. 37 Interestingly, combination therapy increased the number of peripheral Tregs but depleted intra-tumoral Tregs, thereby suggesting that tumor regression largely relies on the depletion of Tregs present in the tumor microenvironment (TME). 37 However, another study using a combination therapy with checkpoint inhibitor antibodies (Abs) like PD-1 showed a negative effect on the anti-tumor activity of OX40 agonist Ab, emphasizing the need for the appropriate design of immunotherapy combinations. 102 
Chemotherapeutic Agents
Several small-molecule chemotherapeutic agents and adjuvant have been found to exert an off-target effect on Tregs that correlate well with their overall anti-cancer efficacy. These include both DNA targeting drugs as well as those that target the biosynthetic pathways or metabolic reprogramming of tumors. In the case of some drugs, the effects on Tregs have been observed at doses significantly lower than the doses used for affecting the primary targets.
Cyclophosphamide
Cyclophosphamide is a DNA crosslinking agent and a widely used anti-cancer drug. 106, 107 Cyclophosphamide decreases the immune system response and is also used in the treatment of autoimmune disorders such as granulomatosis with polyangiis. 108 Cyclophosphamide shows a differential dose-response concerning immune response, where a high dose required for effective anti-tumor chemotherapy may be associated with immunosuppression while a low dose has been demonstrated to show increased anti-tumor immunity in mice models and metastatic melanoma patients. 109, 110 The low dose immune-stimulatory property of cyclophosphamide was first realized when the regression was observed in a cyclophosphamide-resistant lymphoma (L5178Y) in mice. 111, 112 Many studies have demonstrated that cyclophosphamide depletes Tregs in normal 109 and tumor-bearing mice as well as in rats-bearing chemically induced colon cancer (PROb). 25, 106, 113 However, cyclophosphamide does not specifically deplete Tregs (CD4
, since it also reduces T cells (CD4 + CD25 − ). 114 Interestingly, continuous administration of cyclophosphamide at low doses has been shown to inhibit the renewal of Tregs in multiple myeloma-bearing mice and restore the anti-tumor immunity thereby prolonging the overall survival and preventing the tumorrecurrence. 115 We demonstrated that lower doses of cyclophosphamide enhanced radiosensitization by a glycolytic inhibitor 2-DG that could be linked to its ability to deplete iTregs. 116, 117 Reduced Treg infiltration with an increase in CD8 + T cells has been detected in patients with metastatic carcinoma that were treated with cyclophosphamide and immunotherapy (intra-tumor BCG).
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Recent studies have shown that it is the CD8 + resident
DCs that activate Tregs, and the anti-tumor response triggered by cyclophosphamide is due to selective depletion of the CD8 + resident DCs. 119 However, selective depletion of CD8 + resident DCs by cyclophosphamide might compromise the immunity of host when exposed to an infectious pathogen as CD8 + resident DCs serve as APCs for exogenous antigens. In a phase-II trial, progression-free survival was shown in more than 50% of the ovarian cancer patients treated with a combination of bevacizumab and low dose cyclophosphamide (50 mg/day), while trials in hepatocellular carcinoma patients using a low dose of cyclophosphamide impaired Treg suppression and unmasked the Teff cell response against α-fetoprotein in 6 out of 13 patients. 120, 121 The capability of cyclophosphamide to inhibit the suppressive functions of Treg cells, leading to enhanced tumor immunity, entitles it to be an effective chemotherapeutic agent or an adjuvant. 107 
Mitoxantrone
Mitoxantrone is a DNA binding anthracenedione that binds to deoxyribose sugar leading to a strand break.
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Another marked effect of mitoxantrone, which augments anti-cancer immunity, is through cell surface expression of calreticulin in cancer cells, which in turn promotes phagocytosis of dying cancer cells through DCs. 123 Treatment of breast cancer patients with mitoxantrone does not seem to significantly change the CD4 + /CD8 + ratio, but lead to depletion of B lymphocytes and Treg population. 40 Therefore, mitoxantrone can be combined with other modalities to formulate an effective immunotherapeutic regimen for cancer treatment. However, it should be noted that these effects of mitoxantrone could be non-specific and therefore requires further investigations before it can be used for cancer immunotherapy.
Aromatase Inhibitors
The aromatase enzyme plays a key role in estrogen biosynthesis. Estrogen has been attributed to the promotion of immune tolerance by augmenting Treg proliferation in humans and mice. 124, 125 It is well established that Tregs infiltration in tumors results in a shorter survival in breast cancer patients. 126 Therefore, the blocking of estrogen receptor α-signaling by aromatase inhibitors can be exploited as a therapeutic strategy, especially in estrogendependent breast cancer. 126 In a phase-II trial, 83 patients with breast cancer were treated with letrozole, an aromatase inhibitor. The results showed that reduced infiltrating Treg numbers in biopsies correlate well with higher immune response in patients. 127 Furthermore, in a controlled phase-II trial, letrozole-treated patients with breast cancer showed a marked reduction of tumor-infiltrating Tregs in the primary tumor post-therapy. However, combining cyclophosphamide with letrozole did not further affect the frequency of Tregs in the tumor. 127 Furthermore, adverse effects on cognitive functioning have been observed in patients administered with letrozole. 128 Thus, these evidences suggest that aromatase inhibitors cause immunomodulatory events resulting in a targeted decrease in proliferation of tumor infiltrating Tregs and therefore have immunotherapeutic potential but their toxic effects need further consideration.
2-Deoxy-D-Glucose (2-DG)
Metabolic reprogramming (MRP) has emerged as one of the vital features of tumors, wherein the tumor cells reprogram their metabolism by switching to glycolysis despite adequate oxygen rather than the much more efficient oxidative phosphorylation pathway, which is known as the Warburg effect. Moreover, in phase-I-III clinical trials, negligible normal tissue toxicity, enhanced survival and significant improvement in the quality of life has been observed in cerebral glioma patients following administration of 2-DG with hypofractionated radiotherapy. 40, [133] [134] [135] [136] [137] Results from murine studies have shown that the response of the tumors to the combined treatment of 2-DG and irradiation is heterogeneous with complete (cure; tumor-free survival) and partial (growth delay) response, which correlates well with the immune stimulation, switch of Th2 cells to Th1 cells and a significant reduction in Treg numbers in spleen, peripheral blood, lymph node and tumor. 133, 134, 138 139 Since suboptimal TCR engagement occurs in most tumors, 2-DG appears to be a good component for the combination therapy. Thus 2-DG directly sensitizes tumor cells by compromising the energy dependent repair and recovery processes, and also reduces immune tolerance by reducing Tregs. Although, 2-DG is a well-known adjuvant for radio-and chemotherapy of cancer, further studies are required to assess its combination with immunotherapies. 132 It is likely that other anti-cancer therapeutics, besides the one discussed above may also have effects on Tregs, which may partly contribute to their overall efficacy. However, considering them as immune targeting agents is less realistic compared to other immune modulators like checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 antibodies. Besides, several such agents have shown non-specific effects on Tregs and need further investigations before they can be used to target Tregs.
Effects Of Ionizing Radiation On Tregs
Radiation enhances anti-tumor immunity which is associated with alterations in tumor cell phenotype and increased activity of immune cells like CD4 Radiation up-regulates the expression of various adhesion molecules like vascular cell adhesion protein 1 (VCAM-1), E-selectin, and intercellular adhesion molecule 1 (ICAM-1) on endothelial cells, enhancing the leukocyte adhesion and migration, leading to alterations in the TME. 144 Contrarily, radiation enhances the proliferative capacity and activity of Tregs at therapeutic doses leading to immunosuppression and tumor relapse. Recent studies suggest that the major mechanism involved in radio-resistance of Tregs is intrinsically through the high expression of GITR and extrinsically through radiation-induced production of TGF-β; an important cytokine needed for Treg proliferation and activity. 145, 146 Stereotactic radiotherapy has been suggested to enhance the functionality of Treg cells in the TME, which is independent of TGF-β and IL33 thereby indicating the involvement of multiple mechanisms in Tregs radioresistance. 147 Moreover, Tregs show a differential response to a low and high dose of radiation. CTLA4 was found to be upregulated at a low dose (1.8 Gy) and decreased at high dose (30 Gy) suggesting low dose enhanced Treg cell proliferation and activity whereas high dose abolished the suppressive capacity of Tregs attributed to increased apoptosis and pro-apoptotic protein Bax. 12, 146 Tregs have been considered as a major hurdle in realizing the efficacy of radiotherapy and therefore Treg cell-based immunotherapy is recommended in combination with radiation to achieve maximum therapeutic gain. STAT3 inhibition in combination with radiation has been 
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